| Dubbaka Devender Reddy, MD | |
|
335 Us Highway 64, Adamsville, TN 38310-4078 | |
| (731) 632-5499 | |
| (731) 925-2157 |
| Full Name | Dubbaka Devender Reddy |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 335 Us Highway 64, Adamsville, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144328576 | NPI | - | NPPES |
| 3 170816 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0000012083 (Tennessee) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dubbaka Devender Reddy, MD Po Box 655, Savannah, TN 38372-0655 Ph: (731) 925-2300 | Dubbaka Devender Reddy, MD 335 Us Highway 64, Adamsville, TN 38310-4078 Ph: (731) 632-5499 |
News Archive
ImaginAb, Inc. is pleased to announce that it has been awarded a total of $2.3 million in funding from the National Cancer Institute's Small Business Innovation Research program to help further develop diagnostic imaging agents for Positron Emission Tomography.
The Assisted Living Federation of America, today hosted a meeting of 140 executives interested in advancing excellence in senior living. The day-long event at National Harbor, Maryland offered executives briefings on topics shaping their businesses today and peer discussions groups to help find answers to some of the big shared questions on their minds.
Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.
APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.
› Verified 5 days ago
Dr. Glenn P Halke, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 726 E Main St, Adamsville, TN 38310 Phone: 731-925-2300 |